Geoff MacKay #33
Geoff is a skilled Chief Executive with proven success leading highly innovative businesses. He has focused in the field of Regenerative Medicine for the last 15 years and is credited with building the first cell-based technology business model which has attained material commercial success as measured by revenue and profit.
Most recently, Geoff spent 11 years as C.E.O. of Organogenesis Inc. in Boston. This company has treated roughly 1 million patients with living cell-based therapies which constitutes more than the rest of the regulated world combined. Paramount to the success of the company was addressing the major hurdles faced in the field of cell-based regenerative medicine; cost-effective manufacturing, navigating regulators and payers, building a reliable supply chain and an effective commercial infrastructure. These learnings, developed and refined, are directly applicable to the broader field. In addition to financial success, relevant metrics include obtaining the first FDA CBER approval for a mass-produced cell therapy and successfully implementing >50 FDA approved process changes to on-market products.
Geoff has a strong pharma heritage, having spent 11 years at Novartis where he held senior leadership positions within the Immunology franchise in Canada, USA and at the Global office in Basel Switzerland.
Geoff has broad international experience and contacts across pharma, biotech and device industries via leadership roles within the life science industry. Examples include: Chairman of the Board of MassBio, Chairman of the Board of the Alliance of Regenerative Medicine, Advisory Council to the Health Policy Commission for Massachusetts, Deans Advisory Council Western University School of Podiatric Surgery, and Chairman of Audit Committee of the Center for Commercialization of Regenerative Medicine (C.C.R.M.).